Adamis Pharmaceuticals Corp: directors' dealings · United States · SEC (Form 4)

About Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corp. (ticker: ADMP) is a U.S.-based specialty biopharmaceutical company listed on the NASDAQ market in the United States. For French, Belgian, and Swiss investors, it sits in the healthcare/pharma segment with a small-cap profile: the company focuses on developing and commercializing specialty treatments in therapeutic areas such as severe allergic reactions, opioid overdose, respiratory conditions, and inflammatory disease. Its corporate headquarters are in San Diego, California, which places it within one of the most established biotechnology clusters in the United States. The company was founded in the mid-2000s and has been led for many years by Dennis J. Carlo, Ph.D., a co-founder who has served as President and Chief Executive Officer since 2006. That long tenure matters from an analyst perspective because it suggests continuity in strategy through multiple development, regulatory, and commercialization phases. Adamis has historically been a product-focused biotech rather than a broad platform company, and its operating model reflects a deliberate emphasis on targeted, clinically relevant products rather than a large diversified portfolio. Its core business lines are centered on two marketed products and one development program. SYMJEPI® is an FDA-approved epinephrine injection for the emergency treatment of acute allergic reactions, including anaphylaxis. ZIMHI® is an FDA-approved naloxone injection for the emergency treatment of opioid overdose. The company also highlights APC-400 (tempol), a capsule in development. From an investment standpoint, this is a concentrated pipeline: it offers clarity, but it also means the business is highly dependent on the commercial traction, regulatory standing, and execution quality of a limited number of assets. In competitive terms, Adamis operates in markets that are crowded and dominated by larger pharmaceutical players and established specialty companies. Its relative edge is not scale, but rather product focus, clinical relevance, and the potential utility of its emergency-care offerings. At the same time, the company’s smaller size means it is more exposed to commercialization risk, funding constraints, and regulatory or operational setbacks than larger peers. Recent corporate context appears to be especially important. The company’s website references merger-related communications involving DMK Pharmaceuticals and also notes prior NASDAQ compliance updates and product-related news. For investors, that means ADMP should be viewed as a NASDAQ-listed U.S. healthcare name with event-driven characteristics: the equity is tied not only to product execution, but also to corporate actions, compliance milestones, and strategic transactions. In short, Adamis is a niche specialty pharma story with real medical relevance, but it remains a higher-risk, lower-scale investment opportunity that requires careful monitoring of capital structure, regulatory developments, and business combination news.